ImmuCell Q3 Net Income $953K as Sales Jump 46%; Cash Nearly Doubles to $7.9M
ICCC has more than doubled off its 52-week low of $4.52.
Summary
ImmuCell's Q3 10-Q confirms the pre-announced 46% sales growth and $953K net income, and shows cash nearly doubling to $7.9 million with a new $3.0 million credit line in the works.
Key Events · Earnings and Guidance · ICCC
-
Q3 Sales Up 46% to $8.0M
Product sales rose to $8,039,951 from $5,506,122, driven by higher First Defense volumes and price increases; gross profit climbed 50.4% to $3,555,060.
-
Net Income $953K vs Year-Ago Loss
Q3 net income was $952,510 ($0.10 per diluted share) versus a $(139,748) loss; nine-month net income of $4,728,773 includes a $2.0 million one-time settlement.
-
Cash Nearly Doubles to $7.9M
Cash and equivalents reached $7,914,406 at September 30, 2026, up from $3,806,831 at December 31, 2025; operating cash flow was $7,348,008 for the nine months.
-
New $3.0M Credit Line Negotiated
ImmuCell negotiated a new $3,000,000 line of credit with Maine Community Bank, expected to sign in Q4 2026; the prior $1,000,000 facility expired September 11, 2026.
Analysis · ICCC · Life Sciences
The headline numbers were already out, but the 10-Q fills in what matters: cash and equivalents nearly doubled to $7.9 million from $3.8 million at year-end, helped by a $2.0 million settlement with a former contract manufacturer. Nine-month net income of $4.7 million includes that one-time settlement, so the underlying run-rate is thinner than the headline. The company also negotiated a new $3.0 million line of credit to replace the $1.0 million facility that expired September 11, 2026, and says it has funding for at least the next 12 months. Against that, the First Defense capacity expansion still needs another $6.3 million over nine to 15 months, and two distributors account for 71% of sales and 82% of receivables — a concentration that cuts both ways if either pulls back.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ICCC was trading at $10.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92.8M. The 52-week trading range was $4.52 to $12.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.